FDA DEVICE FACTS
AtriClip LAA Exclusion System with Preloaded PRO·V Clip
AtriCure, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The AtriClip LAA Exclusion System is indicated for the occlusion of the heart’s left atrial appendage, performed under direct visualization and in conjunction with other cardiac surgical procedures.
Direct visualization, in this context, requires that the surgeon is able to see the heart directly, with or without assistance from a camera, endoscope, etc., or other appropriate viewing technologies.
V. Comparison of Technological Characteristics (PRO·V cleared via K153500)
Minor dimensional modifications were made to internal components of the end effector of the Clip Applier, and a minor internal component was replaced with an equivalent component in the handle of the Clip Applier. A minor dimensional modification was also made to the PRO·V Clip Implant.
• The devices have the same intended use and;
• No changes were made in operating principle, or specifications of performance.
• No changes were made to the labeling.
• No changes were required in packaging sterilization or expiration dating.
• The PRO·V Clip continues to be made of titanium and polyester.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。